Site icon Premium Alpha

Royalty Pharma plc (RPRX) Presents at UBS International Biopharma Convention 2026 Transcript

Royalty Pharma plc (RPRX) Presents at UBS International Biopharma Convention 2026 Transcript


Royalty Pharma plc (RPRX) UBS International Biopharma Convention 2026 November 17, 2026 5:40 AM EST

Firm Individuals

Christopher Hite – Chairman of Partnering & Investments
Greg Butz – Government Vice President of Partnering & Investments

Convention Name Individuals

Ashwani Verma – UBS Funding Financial institution, Analysis Division

Presentation

Ashwani Verma
UBS Funding Financial institution, Analysis Division

Good day, all people. Thanks a lot for becoming a member of. Welcome again to the subsequent session at UBS Biopharma Convention in London. So I am actually excited to have Royalty Pharma right here and have Chris Hite, who’s the Chairman of Partnering and Investments; and Greg Butz, who’s EVP of Partnering. So thanks, gents, for becoming a member of us.

Christopher Hite
Chairman of Partnering & Investments

Thanks.

Query-and-Reply Session

Ashwani Verma
UBS Funding Financial institution, Analysis Division

Sure, thanks. Type of a really, very distinctive story and really nicely understood by buyers, by some buyers, I’d say. However all the time good to begin with some degree of background simply in order that persons are conscious. And for those who can simply hit a few highlights on a few of the key takeaways from the third quarter earnings as nicely, we are able to begin there.

Christopher Hite
Chairman of Partnering & Investments

Certain. Nicely, thanks once more for having us. We actually recognize the chance. It is an excellent convention. So to begin with perhaps only a background on Royalty Pharma. The corporate is 30 years outdated. We celebrated our thirtieth anniversary not too long ago, actually created with the concept to purchase present royalty streams from hospitals, foundations, universities approach again when, and we nonetheless do this. The corporate went public in 2020. We’re investment-grade rated. Capital deployment publicly acknowledged targets of $2 billion to $2.5 billion a 12 months.

We nonetheless purchase present royalty streams. And — however we have actually kind of morphed the enterprise and grown the enterprise by co-investing



Source link

Exit mobile version